Foghorn Therapeutics (FHTX) News Today $5.08 -0.06 (-1.17%) (As of 12:56 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Wedbush Predicts Lower Earnings for Foghorn TherapeuticsDecember 21 at 3:29 AM | americanbankingnews.comHC Wainwright Has Bullish Outlook for FHTX FY2024 EarningsDecember 21 at 1:37 AM | americanbankingnews.comWedbush Has Pessimistic Outlook of FHTX FY2028 EarningsFoghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) - Equities researchers at Wedbush dropped their FY2028 earnings per share estimates for Foghorn Therapeutics in a research report issued to clients and investors on Monday, December 16th. Wedbush analyst R. Driscoll now forecasts that the compDecember 19, 2024 | marketbeat.comFY2024 Earnings Forecast for FHTX Issued By HC WainwrightFoghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) - Investment analysts at HC Wainwright raised their FY2024 earnings estimates for Foghorn Therapeutics in a note issued to investors on Tuesday, December 17th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings ofDecember 19, 2024 | marketbeat.comJefferies Financial Group Issues Pessimistic Forecast for Foghorn Therapeutics (NASDAQ:FHTX) Stock PriceDecember 18, 2024 | americanbankingnews.comFoghorn Therapeutics’ Strategic Shift and Financial Strength Bolster Buy Rating Amid Promising FHD-909 ProspectsDecember 17, 2024 | markets.businessinsider.comShort Interest in Foghorn Therapeutics Inc. (NASDAQ:FHTX) Decreases By 9.7%Foghorn Therapeutics Inc. (NASDAQ:FHTX - Get Free Report) saw a large drop in short interest in November. As of November 30th, there was short interest totalling 888,000 shares, a drop of 9.7% from the November 15th total of 983,500 shares. Currently, 3.2% of the shares of the stock are short sold. Based on an average daily volume of 155,900 shares, the short-interest ratio is presently 5.7 days.December 17, 2024 | marketbeat.comFoghorn Therapeutics' (FHTX) Buy Rating Reaffirmed at HC WainwrightHC Wainwright reiterated a "buy" rating and set a $13.00 price objective (down from $20.00) on shares of Foghorn Therapeutics in a report on Tuesday.December 17, 2024 | marketbeat.comFoghorn Therapeutics: Hold Rating Amid Strategic Pivot and Uncertainty in Drug DevelopmentDecember 17, 2024 | markets.businessinsider.comJefferies Financial Group Lowers Foghorn Therapeutics (NASDAQ:FHTX) Price Target to $14.00Jefferies Financial Group lowered their target price on Foghorn Therapeutics from $18.00 to $14.00 and set a "buy" rating on the stock in a research report on Monday.December 16, 2024 | marketbeat.comFoghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic PrioritiesDecember 16, 2024 | globenewswire.comFoghorn Therapeutics to Participate in Three Upcoming Investor ConferencesNovember 12, 2024 | globenewswire.comAnalysts Have Made A Financial Statement On Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Third-Quarter ReportNovember 7, 2024 | finance.yahoo.comWhat is HC Wainwright's Forecast for FHTX FY2024 Earnings?Foghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) - Analysts at HC Wainwright raised their FY2024 earnings estimates for Foghorn Therapeutics in a research report issued to clients and investors on Tuesday, November 5th. HC Wainwright analyst A. Fein now expects that the company will post earNovember 7, 2024 | marketbeat.comWhat is Wedbush's Estimate for FHTX FY2024 Earnings?Foghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) - Research analysts at Wedbush lifted their FY2024 EPS estimates for shares of Foghorn Therapeutics in a report issued on Monday, November 4th. Wedbush analyst R. Driscoll now forecasts that the company will earn ($1.57) per share for the yearNovember 7, 2024 | marketbeat.comFoghorn Therapeutics Reports Third Quarter HighlightsNovember 6, 2024 | markets.businessinsider.comOptimistic Buy Rating for Foghorn Therapeutics Amid Promising Phase 1 Study and Strategic Pipeline AdvancementsNovember 6, 2024 | markets.businessinsider.comFoghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate UpdateNovember 4, 2024 | globenewswire.comShort Interest in Foghorn Therapeutics Inc. (NASDAQ:FHTX) Increases By 9.1%Foghorn Therapeutics Inc. (NASDAQ:FHTX - Get Free Report) saw a large increase in short interest in the month of September. As of September 30th, there was short interest totalling 1,200,000 shares, an increase of 9.1% from the September 15th total of 1,100,000 shares. Based on an average daily volume of 152,000 shares, the short-interest ratio is presently 7.9 days. Currently, 4.2% of the shares of the stock are sold short.October 17, 2024 | marketbeat.comFoghorn Therapeutics Unveils Clinical Pipeline ProgressOctober 11, 2024 | finance.yahoo.comFoghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid TumorsOctober 10, 2024 | globenewswire.comFoghorn Therapeutics (NASDAQ:FHTX) Stock, Short Interest ReportOctober 8, 2024 | benzinga.comFoghorn Therapeutics (NASDAQ:FHTX) Stock Quotes, Forecast and News SummaryOctober 8, 2024 | benzinga.comFoghorn Therapeutics to Participate in the BMO Oncology SummitOctober 1, 2024 | globenewswire.comPerceptive Advisors LLC Purchases Shares of 544,000 Foghorn Therapeutics Inc. (NASDAQ:FHTX)Perceptive Advisors LLC acquired a new position in shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 544,000 shares of the company's stock, valueSeptember 30, 2024 | marketbeat.comDeerfield Management Company L.P. Series C Purchases Shares of 2,518,500 Foghorn Therapeutics Inc. (NASDAQ:FHTX)Deerfield Management Company L.P. Series C acquired a new position in shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,518,500 shaSeptember 26, 2024 | marketbeat.comFoghorn Therapeutics Inc. (NASDAQ:FHTX) Insider Sells $358,990.24 in StockSeptember 25, 2024 | insidertrades.comFoghorn Therapeutics: Holding for FHD-286 Clinical Trial Outcomes and Financial Position AnalysisSeptember 24, 2024 | markets.businessinsider.comFoghorn Therapeutics (NASDAQ:FHTX) PT Raised to $9.00 at Morgan StanleyMorgan Stanley upped their price target on Foghorn Therapeutics from $6.00 to $9.00 and gave the company an "equal weight" rating in a research report on Tuesday.September 24, 2024 | marketbeat.comFoghorn Therapeutics Inc. (NASDAQ:FHTX) Sees Large Increase in Short InterestFoghorn Therapeutics Inc. (NASDAQ:FHTX - Get Free Report) saw a significant increase in short interest during the month of August. As of August 31st, there was short interest totalling 1,060,000 shares, an increase of 65.0% from the August 15th total of 642,400 shares. Currently, 3.7% of the company's shares are sold short. Based on an average trading volume of 121,600 shares, the days-to-cover ratio is presently 8.7 days.September 13, 2024 | marketbeat.comFoghorn Therapeutics (NASDAQ:FHTX) Sees Large Volume IncreaseFoghorn Therapeutics (NASDAQ:FHTX) Sees Large Volume IncreaseSeptember 13, 2024 | marketbeat.comInsider Sale: Chief Scientific Officer Steven Bellon Sells 20,000 Shares of Foghorn ...September 11, 2024 | finance.yahoo.comFoghorn Therapeutics (NASDAQ:FHTX) Reaches New 12-Month High at $9.22Foghorn Therapeutics (NASDAQ:FHTX) Hits New 1-Year High at $9.22September 9, 2024 | marketbeat.comJefferies Initiates Coverage of Foghorn Therapeutics (FHTX) with Buy RecommendationSeptember 5, 2024 | msn.comJefferies Financial Group Initiates Coverage on Foghorn Therapeutics (NASDAQ:FHTX)Jefferies Financial Group initiated coverage on Foghorn Therapeutics in a research note on Tuesday. They issued a "buy" rating and a $18.00 target price for the company.September 3, 2024 | marketbeat.comFoghorn Therapeutics Strengthens Leadership Team with Appointment of Anna Rivkin, Ph.D. as Chief Business OfficerSeptember 3, 2024 | globenewswire.comFoghorn Therapeutics to Participate in Two Upcoming Investor Conferences in SeptemberAugust 28, 2024 | globenewswire.comRaymond James & Associates Purchases 107,967 Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX)Raymond James & Associates raised its position in Foghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) by 4.8% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,338,423 shares of the company's stoAugust 24, 2024 | marketbeat.comFoghorn Therapeutics Inc. (FHTX)August 24, 2024 | finance.yahoo.comFoghorn Therapeutics Inc Ordinary SharesAugust 21, 2024 | morningstar.comEvercore ISI Group Initiates Coverage of Foghorn Therapeutics (FHTX) with Outperform RecommendationAugust 20, 2024 | msn.comFoghorn Therapeutics (NASDAQ:FHTX) Research Coverage Started at Evercore ISIEvercore ISI initiated coverage on Foghorn Therapeutics in a research report on Monday. They issued an "outperform" rating and a $20.00 target price for the company.August 19, 2024 | marketbeat.comFoghorn Therapeutics Inc. Expected to Earn Q3 2024 Earnings of ($0.42) Per Share (NASDAQ:FHTX)Foghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) - Stock analysts at HC Wainwright upped their Q3 2024 earnings estimates for shares of Foghorn Therapeutics in a research report issued on Monday, August 12th. HC Wainwright analyst A. Fein now anticipates that the company will earn ($0.42) peAugust 15, 2024 | marketbeat.comFoghorn Therapeutics Drug Candidates FHD-286 and FHD-909 Show Promise in Early Trials, Justifying Buy RatingAugust 12, 2024 | markets.businessinsider.comWedbush Keeps Their Buy Rating on Foghorn Therapeutics (FHTX)August 10, 2024 | markets.businessinsider.comFoghorn Therapeutics Provides Second Quarter 2024 Financial and Corporate UpdateAugust 8, 2024 | globenewswire.comJacobs Levy Equity Management Inc. Raises Stock Holdings in Foghorn Therapeutics Inc. (NASDAQ:FHTX)Jacobs Levy Equity Management Inc. grew its stake in shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) by 101.1% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 216,270 shares of the companyAugust 2, 2024 | marketbeat.comInstitutional investors own a significant stake of 36% in Foghorn Therapeutics Inc. (NASDAQ:FHTX)July 29, 2024 | finance.yahoo.comFoghorn Therapeutics Inc. (NASDAQ:FHTX) Short Interest UpdateFoghorn Therapeutics Inc. (NASDAQ:FHTX - Get Free Report) was the recipient of a significant growth in short interest during the month of July. As of July 15th, there was short interest totalling 1,260,000 shares, a growth of 15.6% from the June 30th total of 1,090,000 shares. Based on an average daily trading volume, of 102,900 shares, the days-to-cover ratio is presently 12.2 days. Currently, 4.0% of the company's stock are short sold.July 29, 2024 | marketbeat.comFoghorn Therapeutics Inc. (NASDAQ:FHTX) Short Interest Up 10.6% in JuneFoghorn Therapeutics Inc. (NASDAQ:FHTX - Get Free Report) was the recipient of a large increase in short interest during the month of June. As of June 30th, there was short interest totalling 1,090,000 shares, an increase of 10.6% from the June 15th total of 985,300 shares. Based on an average daily trading volume, of 102,700 shares, the short-interest ratio is currently 10.6 days. Currently, 3.5% of the company's stock are sold short.July 16, 2024 | marketbeat.com Get Foghorn Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FHTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Vacuum up cash with these special trades? (Ad)Have you ever heard about a “volatility vacuum?” Most people haven’t. It all revolves around this formula right here. Now, the most important thing is that this equation — when applied to certain tickers at a certain time each month —- can trigger these “volatility vacuums.” And when that happens, anyone has the shot at sucking out payouts of $290, $350, even $1,350 in as little as 24 hours. (With just a $1k starting stake!) Granted, there were smaller wins and those that did not work out but best of all, we can know exactly when these opportunities will hit. I’ve used this info to create a Cash Calendar that lays out the precise dates of these payouts. And I’m sending it for FREE to anyone who joins me during my FREE training right here. FHTX Media Mentions By Week FHTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FHTX News Sentiment▼0.140.60▲Average Medical News Sentiment FHTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FHTX Articles This Week▼182▲FHTX Articles Average Week Get Foghorn Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FHTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ARS Pharmaceuticals News Today Rocket Pharmaceuticals News Today Avadel Pharmaceuticals News Today Bicycle Therapeutics News Today Collegium Pharmaceutical News Today Septerna News Today Zymeworks News Today Bicara Therapeutics News Today Gyre Therapeutics News Today Poseida Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FHTX) was last updated on 12/23/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Foghorn Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Foghorn Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
